Abbott Laboratories (ABT) Stock Forecast & Price Target

$86.25 -0.92 (-1.05%)

Closing price 03:59 PM Eastern

Extended Trading

$86.43 +0.18 (+0.21%)

As of 07:59 PM Eastern

Compare

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
0

Hold
5

Buy
21

Based on 26 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 5 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$119.43
38.47% Upside

According to the 26 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $119.43. The highest price target for ABT is $143.00, while the lowest price target for ABT is $92.00. The average price target represents a forecasted upside of 38.47% from the current price of $86.25.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

Type	Current Forecast 5/6/25 to 5/6/26	1 Month Ago 4/6/25 to 4/6/26	3 Months Ago 2/5/25 to 2/5/26	1 Year Ago 5/6/24 to 5/6/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	19 Buy rating(s)	15 Buy rating(s)	16 Buy rating(s)	13 Buy rating(s)
Hold	5 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$119.43	$135.47	$137.05	$143.31
Forecasted Upside	38.47% Upside	32.43% Upside	25.70% Upside	7.55% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	37.12% Upside	975.28% Upside	14.01% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
4/27/2026	BTIG Research 2 of 5 stars	Marie Thibault 1 of 5 stars	Reiterated Rating	Buy	$131.00	+43.71%
4/24/2026	Weiss Ratings Not Rated		Downgrade	Hold (C) ➝ Hold (C-)
4/22/2026	Daiwa Securities Group 3 of 5 stars		Downgrade	Outperform ➝ Neutral	$92.00	-0.89%
4/21/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$140.00 ➝ $125.00	+30.13%
4/21/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$119.00 ➝ $106.00	+10.35%
4/20/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$158.00 ➝ $135.00	+40.54%
4/20/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$144.00 ➝ $143.00	+47.59%
4/17/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$135.00 ➝ $130.00	+36.73%
4/17/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$125.00 ➝ $110.00	+15.70%
4/17/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$134.00 ➝ $120.00	+26.22%

4/17/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$130.00 ➝ $115.00	+20.96%
4/17/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$125.00 ➝ $115.00	+20.96%
4/17/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$122.00 ➝ $109.00	+14.65%
4/17/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Overweight	$123.00 ➝ $110.00	+15.70%
4/17/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$135.00 ➝ $115.00	+20.96%
4/17/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$145.00 ➝ $135.00	+41.99%
4/17/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$136.00 ➝ $108.00	+13.59%
4/17/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$137.00 ➝ $115.00	+20.96%
4/17/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$132.00 ➝ $115.00	+20.96%
4/17/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
4/17/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$145.00 ➝ $120.00	+26.22%
4/17/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$150.00 ➝ $120.00	+26.22%
4/8/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$140.00 ➝ $121.00	+18.90%
1/29/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
11/20/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$127.00 ➝ $137.00	+3.75%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:50 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, May 3, 2026. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

The current stock price is around $115, reflecting a strong market position and investor confidence in the company's growth potential.
Abbott Laboratories recently reported quarterly earnings that exceeded analyst expectations, indicating robust financial health and operational efficiency.
The company has a solid dividend yield of approximately 2.8%, providing a steady income stream for investors.
Abbott Laboratories has a diverse portfolio across diagnostics, medical devices, nutritionals, and pharmaceuticals, which helps mitigate risks associated with market fluctuations.
Analysts have a favorable outlook on the stock, with a majority rating it as a "Buy," suggesting potential for price appreciation.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

The stock has seen target price reductions from several analysts, which may indicate concerns about future growth prospects.
Insider trading activity shows a slight decrease in ownership, which could signal a lack of confidence among executives.
The company's price-to-earnings ratio is relatively high, suggesting that the stock may be overvalued compared to its earnings potential.
Abbott Laboratories faces intense competition in the healthcare sector, which could impact its market share and profitability.
The dividend payout ratio is over 70%, indicating that a significant portion of earnings is being distributed to shareholders, which may limit reinvestment in growth opportunities.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $119.43, with a high forecast of $143.00 and a low forecast of $92.00.
: 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 5 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 38.47% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 2 downgrades by analysts.
: Abbott Laboratories has been rated by research analysts at Argus, Bank of America, Barclays, Benchmark, BTIG Research, Citigroup, Daiwa Securities Group, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Oppenheimer, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.
: Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

This page (NYSE:ABT) was last updated on 5/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABT Analyst Ratings Over Time

ABT Analyst Recommendations By Month

ABT Price Targets by Month

Abbott Laboratories Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

Abbott Laboratories
Bull Case

Abbott Laboratories
Bear Case

ABT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

ABT Analyst Ratings Over Time

ABT Analyst Recommendations By Month

ABT Price Targets by Month

Abbott Laboratories Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

Abbott Laboratories Bull Case

Abbott Laboratories Bear Case

ABT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Abbott Laboratories Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Abbott Laboratories
Bull Case

Abbott Laboratories
Bear Case